세계의 메타게놈 시퀀스 시장 규모 : 워크플로우별, 제품·서비스별, 기술별, 용도별, 지역 범위별, 예측

Metagenomic Sequencing Market Size And Forecast

Metagenomic Sequencing Market size was valued at USD 1049.98 Million in 2024 and is projected to reach USD 1648.63 Million by 2032, growing at a CAGR of 6.40% from 2026 to 2032.

The Metagenomic Sequencing Market is defined as the commercial sector encompassing the products, services, and technologies used for the high-throughput analysis of genetic material from environmental samples. This market provides tools and solutions for studying the collective genomes of entire microbial communities, rather than individual organisms.

Key components of this market include:

Instruments: Sequencing machines and related hardware.

Reagents & Consumables: Kits and chemical reagents for sample processing and library preparation.

Sequencing Services: Outsourced services for labs and researchers who do not have their own sequencing equipment.

Bioinformatics Software & Data Analysis: Computational tools for processing, analyzing, and interpreting the massive datasets generated by metagenomic sequencing.

The market is driven by the growing demand for understanding the role of microbial communities in various fields, including:

Clinical Diagnostics: Identifying pathogens and analyzing the human microbiome to understand its role in health and disease.

Environmental Monitoring: Assessing microbial diversity in soil, water, and other ecosystems.

Drug Discovery: Discovering new genes, enzymes, and metabolic pathways for pharmaceutical and biotechnological applications.

Agriculture: Improving soil health and crop yield through the study of plant-associated microbiomes.

The market is characterized by ongoing technological advancements, such as the development of more efficient and affordable sequencing platforms, and the integration of artificial intelligence and machine learning to handle complex data analysis.

Global Metagenomic Sequencing Market Drivers

The metagenomic sequencing market is experiencing rapid expansion, propelled by several significant factors. This revolutionary technology, which allows for the comprehensive analysis of entire microbial communities within a sample, is becoming indispensable across diverse scientific and medical disciplines. Understanding these key drivers is crucial for stakeholders looking to capitalize on this burgeoning market.

Growing Applications in Personalized Medicine: The burgeoning field of personalized medicine stands as a powerful catalyst for the metagenomic sequencing market. As healthcare shifts towards highly individualized treatments, the ability to understand a patient's unique microbial landscape becomes paramount. Metagenomic sequencing provides unprecedented insights into the human microbiome, revealing how microbial communities interact with host genetics, lifestyle, and disease states. This deep understanding enables the development of tailored therapeutic strategies, from optimizing drug dosages to designing probiotic interventions. For instance, analyzing an individual's gut microbiome through metagenomics can predict their response to certain medications or guide dietary recommendations for chronic conditions. The trend towards precision healthcare, where treatments are customized for maximum efficacy and minimal side effects, will continue to drive the demand for comprehensive genomic and metagenomic profiling, positioning this technology at the forefront of personalized medicine.

Increasing Prevalence of Infectious Diseases: The persistent global challenge of infectious diseases is another critical driver for the metagenomic sequencing market. Traditional diagnostic methods can often be slow, expensive, and limited in their ability to identify novel or uncommon pathogens. Metagenomic sequencing, however, offers a powerful solution by providing a rapid, unbiased, and comprehensive method for pathogen detection. By sequencing all genetic material in a sample, it can identify bacteria, viruses, fungi, and parasites simultaneously, even those that are difficult to culture or have not been previously characterized. This capability is invaluable in outbreak investigations, identifying the source of infections, and monitoring antimicrobial resistance patterns. The urgent need for faster, more accurate, and broader-spectrum diagnostic tools to combat emerging infectious diseases and improve public health outcomes ensures a sustained and growing demand for metagenomic sequencing technologies worldwide.

Rising Investments in Genomics Research: Substantial and sustained investments in genomics research globally are significantly bolstering the metagenomic sequencing market. Governments, academic institutions, and private biotech firms are channeling considerable funding into projects aimed at unraveling the complexities of genomes and microbiomes. These investments fuel technological innovation, leading to the development of more efficient, accurate, and cost-effective sequencing platforms, as well as sophisticated bioinformatics tools for data analysis. Research initiatives focused on understanding microbial diversity, host-microbe interactions, and the functional roles of microbial communities in various ecosystems directly translate into an increased adoption of metagenomic sequencing. As researchers uncover new applications and deepen our understanding of biology through genomic insights, the demand for advanced sequencing capabilities will only intensify, creating a fertile ground for the continued expansion and evolution of the metagenomic sequencing market.

Global Metagenomic Sequencing Market Restraints

The global metagenomic sequencing market, while experiencing significant growth, faces several key restraints that challenge its widespread adoption and development. These limitations, from high costs to complex data analysis, can impact the market's trajectory, particularly in developing economies and for smaller research labs. Understanding these challenges is crucial for stakeholders to navigate the market effectively and for innovators to develop solutions that overcome these hurdles.

High Costs and Budgetary Constraints: A primary restraint of the metagenomic sequencing market is the high cost associated with the technology. This isn't just about the price of the sequencing instruments themselves, which can run into the hundreds of thousands of dollars, but also the significant expenses involved in sample preparation, reagents, and specialized consumables. The NovaSeq 5000 and 6000, two of Illumina's leading platforms, can be priced at $850,000 and $985,000, respectively, making them a prohibitive investment for many academic and research institutions, particularly in developing countries. Even as the cost per sequenced genome has decreased over time, the overall budget required for a complete metagenomic project including sequencing, data analysis, and expert personnel remains a major barrier that limits adoption and market growth.

Complex Data Analysis and Bioinformatics Challenges: Metagenomic sequencing generates an enormous volume of data, creating a significant challenge for analysis and interpretation. The data is often from a vast and complex microbial community, with many organisms lacking a reference genome in existing databases. This makes it difficult to accurately classify and quantify the microbes present. The lack of standardized data management and analytical tools also presents a major hurdle. Researchers and clinicians need a high level of expertise in bioinformatics to handle the data, which includes filtering raw reads, assembling fragmented genomes (or "bins"), and assigning functions to newly discovered genes. The need for specialized, highly skilled professionals to manage these complex workflows is a major constraint, as a shortage of such talent can slow down research and clinical implementation.

Lack of Standardization and Reproducibility: Another significant restraint is the lack of standardization across the entire metagenomic workflow. From the initial sample collection and DNA extraction to sequencing protocols and data analysis pipelines, variations can lead to inconsistent and irreproducible results. For example, different DNA extraction methods may introduce biases by being more or less efficient at lysing certain types of microbes, thus skewing the final community profile. This lack of standardized protocols creates a challenge for comparing results between different studies, laboratories, and even continents. Without reliable and reproducible methods, it becomes difficult to establish a clear benchmark for quality and to use metagenomic sequencing for clinical diagnostics, where consistency is paramount for patient care and regulatory approval.

Regulatory and Ethical Hurdles: As metagenomic sequencing moves from a research tool to a clinical diagnostic method, it faces increasing regulatory and ethical scrutiny. In clinical settings, technologies used for diagnosing diseases must undergo rigorous validation and regulatory approval to ensure they are safe and effective. This process can be lengthy and expensive, slowing down the commercialization and clinical adoption of new metagenomic tests. Furthermore, ethical concerns arise, particularly when dealing with the human microbiome. Questions about data privacy, informed consent, and the potential misuse of an individual's microbiome profile are complex and require clear guidelines. The absence of a robust regulatory framework to address these issues is a significant restraint on the market's growth, especially in applications related to personalized medicine and public health.

Global Metagenomic Sequencing Market: Segmentation Analysis

The Global Metagenomic Sequencing Market is Segmented on the basis of Workflow, Product and Services, Technology, Application, And Geography.

Metagenomic Sequencing Market, By Workflow

Sample Processing & Library Preparation

Sequencing

Data Processing & Analysis

Based on Workflow, the Metagenomic Sequencing Market is segmented into Sample Processing & Library Preparation, Sequencing, and Data Processing & Analysis. At VMR, we observe that the Sequencing subsegment holds a dominant position, accounting for a significant market share, with estimates often placing it at over 50% of the total revenue contribution. This dominance is driven by the continuous technological advancements in Next-Generation Sequencing (NGS) platforms from key players such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies. The dramatic decline in sequencing costs, along with a significant increase in throughput and accuracy, has made large-scale metagenomic projects feasible and highly attractive for a wide range of applications. The demand for sequencing is particularly strong in North America, a region that leads the market due to robust R&D spending, the presence of major biotech companies and academic institutions, and a strong focus on precision medicine and drug discovery. The Sequencing subsegment is the core engine of the market, as it generates the massive data sets required for all downstream analysis and is essential for key end-users in drug discovery and clinical diagnostics.

The Sample Processing & Library Preparation subsegment is the second most dominant in the workflow, with a crucial role as the foundational step of any metagenomic project. Its growth is fueled by the need for specialized kits and reagents that minimize contamination and ensure high-quality, representative DNA from complex samples like soil, water, and the human gut. This segment's importance is underscored by the fact that the quality of the raw data is directly dependent on the initial sample preparation, making it a critical bottleneck and a focus for innovation. The growth of this subsegment is supported by the increasing number of research projects and the expansion of metagenomic applications in new industries, which require tailored protocols. Finally, the Data Processing & Analysis subsegment, while currently smaller in revenue, is projected to be the fastest-growing component of the workflow. The exponential volume of data generated by modern sequencers has created a burgeoning demand for advanced bioinformatics software, AI-driven analytical tools, and cloud-based platforms to handle the complexity of microbial community data. The future potential of this subsegment is immense, as it directly addresses the critical challenges of data interpretation and is essential for extracting actionable insights from the raw sequencing data for end-users in academia, pharmaceuticals, and environmental science.

Metagenomic Sequencing Market, By Product and Services

Reagents & Consumables

Instruments

Services

Based on Product and Services, the Metagenomic Sequencing Market is segmented into Reagents & Consumables, Instruments, Services. At VMR, we observe that the Reagents & Consumables subsegment holds the dominant market share, often exceeding 55%, due to its fundamental and recurring role in nearly every sequencing project. This dominance is driven by the consistent need for a wide array of kits, enzymes, and other chemical agents necessary for DNA/RNA extraction, library preparation, and sequencing on a per-run basis. The segment is further propelled by the increasing adoption of high-throughput sequencing in key industries such as clinical diagnostics and drug discovery, particularly in North America, which is the leading regional market due to significant R&D investments and the presence of major life sciences companies. Technological advancements, including the development of more efficient and cost-effective library preparation kits, are a key market trend supporting this subsegment's growth.

The second most dominant subsegment, Instruments, represents the essential hardware platforms like next-generation sequencers (NGS) that enable the entire workflow. Although a high-value, one-time capital expenditure, this segment is a significant revenue contributor, with its growth supported by continuous technological innovation, which has led to a dramatic decline in the cost per run, making sequencing more accessible. The Services subsegment, while smaller in market share, is the fastest-growing component of the market, with a projected CAGR of over 17%. Its role is to provide specialized sequencing, data analysis, and interpretation to researchers, hospitals, and companies that lack the internal infrastructure or bioinformatic expertise. This subsegment's expansion is fueled by the sheer volume of data generated by modern sequencers and the growing complexity of bioinformatics, highlighting a future market shift toward expert-driven data solutions.

Metagenomic Sequencing Market, By Technology

Shotgun Metagenomic Sequencing

16S rRNA Sequencing

Metatranscriptomics

Whole-genome Sequencing & De Novo Assembly

Based on Technology, the Metagenomic Sequencing Market is segmented into Shotgun Metagenomic Sequencing, 16S rRNA Sequencing, Metatranscriptomics, and Whole-genome Sequencing & De Novo Assembly. At VMR, we observe that Shotgun Metagenomic Sequencing is the dominant technology, capturing a significant market share, with some reports indicating its revenue contribution is over 40%. Its dominance stems from its ability to provide a comprehensive, unbiased view of an entire microbial community, sequencing all DNA in a sample, including bacteria, viruses, fungi, and archaea. This holistic approach is a key driver for its adoption in a wide array of applications, from human microbiome analysis to environmental studies and infectious disease surveillance. The decline in sequencing costs, coupled with advancements in bioinformatics tools and AI-driven data analysis, has made this powerful technology more accessible, fueling its growth, particularly in North America, where robust R&D funding and a strong presence of biotech and pharmaceutical companies drive high demand.

The second most dominant subsegment is 16S rRNA Sequencing, which, while less comprehensive than shotgun sequencing, remains highly popular due to its cost-effectiveness and well-established protocols for taxonomic profiling. It targets a specific, conserved gene region in bacteria and archaea, making it ideal for studies focused on microbial diversity and community composition. This technology continues to be a staple in academic research and is often used for preliminary microbiome studies before a deeper, more expensive shotgun approach is considered. The remaining subsegments, including Metatranscriptomics and Whole-genome Sequencing & De Novo Assembly, occupy a more niche yet rapidly expanding role. Metatranscriptomics focuses on sequencing RNA to understand the active gene expression and functional potential of microbial communities, while Whole-genome Sequencing & De Novo Assembly is a specialized method used to reconstruct complete microbial genomes from complex samples, particularly for novel, unculturable organisms. These technologies represent the future of the market, addressing more complex research questions and supporting advanced applications in drug discovery and novel pathogen identification.

Metagenomic Sequencing Market, By Application

Drug Discovery

Clinical Diagnostics

Soil Microbiome

Ecological and Environmental

Based on Application, the Metagenomic Sequencing Market is segmented into Drug Discovery, Clinical Diagnostics, Soil Microbiome, Ecological and Environmental. At VMR, we observe that the Drug Discovery subsegment is currently the dominant application, holding a significant market share and driving substantial revenue. This dominance is propelled by several key market drivers and industry trends. Pharmaceutical and biotechnology companies are increasingly leveraging metagenomic sequencing to explore the vast, untapped microbial biodiversity for the discovery of novel drug targets, enzymes, and bioactive compounds, particularly for addressing antimicrobial resistance and developing personalized medicines. The adoption is high in North America, which benefits from robust R&D expenditure, extensive government and private funding for genomic research, and the presence of major industry players. This trend is further fueled by the integration of AI and machine learning for bioinformatics, which helps analyze the massive datasets generated by sequencing, accelerating the drug development pipeline.

The Clinical Diagnostics subsegment holds the second-largest position, experiencing rapid growth. This segment's expansion is driven by the rising demand for quick and accurate pathogen detection and diagnosis of infectious diseases. Metagenomics offers a powerful alternative to traditional culture-based methods by identifying a wide range of microorganisms, including those that are difficult to culture, from clinical samples. This is particularly impactful in the Asia-Pacific region, where improving healthcare infrastructure and growing awareness of advanced diagnostic technologies are fueling market growth. The remaining subsegments, including Soil Microbiome and Ecological and Environmental, play a supporting yet crucial role, catering to niche applications. These areas are vital for advancing sustainable agriculture, environmental monitoring, and bioremediation, though their market adoption is more focused on academic research and specific industrial projects. While smaller in revenue contribution today, their future potential is high, especially as global interest in climate change and sustainable practices grows.

Metagenomic Sequencing Market, By Geography

North America

Asia Pacific

Europe

Latin America

Middle East & Africa

The Metagenomic Sequencing market is a specialized and rapidly expanding segment of the life sciences and biotechnology industries. It involves the direct genetic analysis of all genomes within an environmental sample, such as soil, water, or human microbiome. This approach allows researchers to study complex microbial communities without the need for traditional lab cultivation, providing powerful insights into biodiversity, disease diagnosis, drug discovery, and environmental science. The market's growth is fueled by advancements in next-generation sequencing (NGS) technologies, declining sequencing costs, and a heightened focus on personalized medicine and environmental sustainability.

United States Metagenomic Sequencing Market

The United States holds the dominant position in the global metagenomic sequencing market, driven by its robust R&D infrastructure, significant government and private funding, and the presence of leading sequencing technology companies.

Market Dynamics: The U.S. market is characterized by a strong ecosystem of academic and research institutions, pharmaceutical and biotechnology companies, and a well-established healthcare system. Metagenomics is a key tool in ongoing large-scale research projects, such as the NIH's "All of Us" Research Program, which aims to collect diverse genetic data to advance precision medicine. The market is also highly competitive, with major players continuously innovating to improve sequencing platforms and data analysis tools.

Key Growth Drivers: The extensive research in genomics, oncology, and whole-genome sequencing is a primary driver. The growing demand for personalized medicine and targeted therapies is accelerating the use of metagenomic sequencing to understand the role of the human microbiome in disease. Furthermore, significant funding from government agencies and private investment firms for genomics research and infrastructure development is a major catalyst.

Current Trends: A key trend is the integration of metagenomic sequencing into clinical diagnostics for infectious diseases and gastrointestinal disorders. The decreasing cost of sequencing, due to advancements in NGS platforms like Illumina's NovaSeq X series, is making the technology more accessible. There is also a rising focus on microbiome analysis using both 16S rRNA gene amplicons and shotgun metagenomics, providing a more comprehensive understanding of microbial communities.

Europe Metagenomic Sequencing Market

Europe is the second-largest market for metagenomic sequencing, with its growth propelled by strong government support for research, a robust academic community, and increasing applications in clinical diagnostics and biotechnology.

Market Dynamics: The European market benefits from well-funded research initiatives and a collaborative environment among academic institutions and private companies. Countries like Germany, the UK, and France are at the forefront of metagenomics research. The market is also heavily influenced by regulatory frameworks, particularly regarding data privacy and the ethical use of genetic information.

Key Growth Drivers: The availability of research funding and the presence of leading research organizations are significant drivers. The growing use of metagenomics in clinical diagnostics, especially for infectious diseases and in drug discovery, is also fueling market growth. Furthermore, the increasing awareness of the link between the microbiome and human health is expanding the application of metagenomics.

Current Trends: The market is seeing a high adoption of next-generation sequencing technologies. There is a strong focus on using metagenomic sequencing for environmental applications, such as bioprospecting and environmental remediation. The development of portable and user-friendly sequencing devices, such as those from Oxford Nanopore Technologies, is making metagenomics accessible outside of traditional laboratory settings.

Asia-Pacific Metagenomic Sequencing Market

The Asia-Pacific (APAC) region is projected to be the fastest-growing market for metagenomic sequencing, driven by rapid advancements in healthcare infrastructure, increasing research funding, and a large patient population.

Market Dynamics: The APAC market is dynamic and diverse, with countries like China, Japan, South Korea, and India investing heavily in genomics and biotechnology. The region's large and growing patient population, particularly in infectious and chronic diseases, is creating a significant demand for advanced diagnostic and research tools. Government initiatives and strategic collaborations are also playing a crucial role in market expansion.

Key Growth Drivers: The increasing investments in healthcare and research activities are a primary driver. The growing adoption of personalized medicine and the need for accurate diagnostics, particularly for infectious diseases and antimicrobial resistance, are accelerating the use of metagenomic sequencing. Furthermore, the rising awareness of microbial diversity and its impact on health is driving demand from both academic and clinical sectors.

Current Trends: The market is witnessing a high growth rate in the clinical testing segment, driven by the need for precise and non-invasive diagnostic techniques. The integration of next-generation sequencing (NGS), bioinformatics, and AI-driven analysis is a key trend to enhance the accuracy and efficiency of metagenomic profiling. The decline in sequencing costs is also making the technology more accessible to a broader range of end-users in the region.

Latin America Metagenomic Sequencing Market

The Latin American metagenomic sequencing market is in its early stages of development but shows significant potential, driven by growing investments in healthcare and a rising awareness of the link between the microbiome and disease.

Market Dynamics: The market is characterized by a high reliance on imported sequencing technologies and a growing number of research initiatives. Countries like Brazil and Mexico are leading the way, with a focus on applying metagenomics in public health, agriculture, and environmental research. The market faces challenges related to high costs and the need for skilled bioinformatics professionals.

Key Growth Drivers: Advancements in sequencing technologies and a rising demand for personalized medicine are key drivers. The increasing number of research initiatives in microbiome-based therapeutics and the expanding clinical applications in chronic disease management are also contributing to market growth. Supportive government collaborations with international organizations are helping to overcome resource limitations.

Current Trends: The market is witnessing a growing recognition of the microbiome's critical role in human health, which is driving demand for sequencing services. There is a strong interest in using metagenomics for agricultural applications, such as improving crop yields and soil health. Partnerships with international sequencing providers are strengthening the regional market and helping to build local expertise.

Middle East & Africa Metagenomic Sequencing Market

The Middle East & Africa (MEA) region is an emerging market for metagenomic sequencing, with significant growth potential, especially in the Middle East, driven by government investments in healthcare and life sciences research.

Market Dynamics: The MEA market is still in its nascent stage, with a high concentration of research and diagnostic activities in countries like Saudi Arabia and the UAE. The market is characterized by significant government and private funding for large-scale genomics projects aimed at modernizing healthcare systems and improving disease diagnosis.

Key Growth Drivers: The primary drivers are the rising incidence of genetic disorders and infectious diseases. Government initiatives to advance genomic research and precision medicine are also major catalysts. The growing collaboration between international sequencing companies and local academic and research institutions is helping to build regional expertise.

Current Trends: The market is witnessing a strong preference for advanced sequencing technologies for use in diagnostics and drug discovery. There is a growing interest in using metagenomics for a wide range of applications, including disease diagnosis, biomarker discovery, and environmental monitoring. Challenges such as the high cost of sequencing instruments and a shortage of skilled bioinformatics experts are being addressed through strategic initiatives and international partnerships.

Key Players

The "Global Metagenomic Sequencing Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., PerkinElmer, Oxford Nanopore Technologies Ltd., BGI Group, Macrogen Inc., GENEWIZ, Eurofins Scientific, Novogene Corporation. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH DEPLOYMENT METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL METAGENOMIC SEQUENCING MARKET OVERVIEW
• 3.2 GLOBAL METAGENOMIC SEQUENCING MARKET ESTIMATES AND FORECAST (USD MILLION)
• 3.3 GLOBAL BIOGAS FLOW METER ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL METAGENOMIC SEQUENCING MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY WORKFLOW
• 3.8 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT AND SERVICES
• 3.9 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
• 3.10 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.11 GLOBAL METAGENOMIC SEQUENCING MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.12 GLOBAL METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
• 3.13 GLOBAL METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
• 3.14 GLOBAL METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY(USD MILLION)
• 3.15 GLOBAL METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
• 3.16 GLOBAL METAGENOMIC SEQUENCING MARKET, BY EEEE (USD MILLION)
• 3.17 GLOBAL METAGENOMIC SEQUENCING MARKET, BY GEOGRAPHY (USD MILLION)
• 3.18 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL METAGENOMIC SEQUENCING MARKET EVOLUTION
• 4.2 GLOBAL METAGENOMIC SEQUENCING MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE COMPONENTS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY WORKFLOW

• 5.1 OVERVIEW
• 5.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY WORKFLOW
• 5.3 SAMPLE PROCESSING & LIBRARY PREPARATION
• 5.4 SEQUENCING
• 5.5 DATA PROCESSING & ANALYSIS

6 MARKET, BY PRODUCT AND SERVICES

• 6.1 OVERVIEW
• 6.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT AND SERVICES
• 6.3 REAGENTS & CONSUMABLES
• 6.4 INSTRUMENTS
• 6.5 SERVICES

7 MARKET, BY TECHNOLOGY

• 7.1 OVERVIEW
• 7.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TECHNOLOGY
• 7.3 SHOTGUN METAGENOMIC SEQUENCING
• 7.4 16S RRNA SEQUENCING
• 7.5 METATRANSCRIPTOMICS
• 7.6 WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY

8 MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 8.3 DRUG DISCOVERY
• 8.4 CLINICAL DIAGNOSTICS
• 8.5 SOIL MICROBIOME
• 8.6 ECOLOGICAL AND ENVIRONMENTAL

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 U.S.
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 U.K.
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
  • 9.5.2 ARGENTINA
  • 9.5.3 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST AND AFRICA
  • 9.6.1 UAE
  • 9.6.2 SAUDI ARABIA
  • 9.6.3 SOUTH AFRICA
  • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY DEVELOPMENT STRATEGIES
• 10.3 COMPANY REGIONAL FOOTPRINT
• 10.4 ACE MATRIX
  • 10.4.1 ACTIVE
  • 10.4.2 CUTTING EDGE
  • 10.4.3 EMERGING
  • 10.4.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 OVERVIEW
• 11.2 ILLUMINA INC
• 11.3 THERMO FISHER SCIENTIFIC INC
• 11.4 QIAGEN N.V.
• 11.5 PERKINELMER
• 11.6 OXFORD NANOPORE TECHNOLOGIES LTD.
• 11.7 BGI GROUP
• 11.8 MACROGEN INC
• 11.9 GENEWIZ
• 11.10 EUROFINS SCIENTIFIC
• 11.11 NOVOGENE CORPORATION